Just now at 3:20 ET, they were talking about the recent American Society of Hematology meeting that occurred over the weekend and how that led to Eisai's purchase of MGI Pharma. Pluristem was there. They specifically stated that the most attractive small biotech company's are those that have hematology/oncology based products that may have multiple uses to provide for steady long term income. They mentioned that MANY large pharma companies have poor pipelines and are looking to beef them up.

That is exactly what pluristem's product could be. Albeit, it is too early to say that pluristem has a viable commercial product. They NEED to get through their phase 1 studies to prove safety. Then, more big pharma companies will be looking to snatch this up. IF it has any potential, and pluristem's product has tremendous potential, pharma is willing to take the chance to buy out the product or finance trials because it is MUCH MUCH CHEAPER and EASIER then trying to develop their own product in-house.